Our Services.

Clinical Registries

Data driven outcomes with longitudinal Real World Data (RWD) to generate Real World Evidence (RWE) for Scientific Research and Evidence-Based Medicine

Electronic Patient Reported Outcome Measurements (ePROMs)

Digital symptom monitoring to improve patients` overall survival and quality of life

AI and Machine Learning

Unlock the power of EHR, streamline workflows, improve database maintenance. Report and visualize more accurate results automatically

Your Benefits.

Real World Data for Medical Research and Personalized Medicine

Lower costs while improving outcomes

Connect to Cure: generate and connect RWD and ePROMs in routine clinical care

Close the bridge between decision-makers across life science, health insurance and provider organizations

Overcome limiting factors through Machine Learning (ML) and Natural Language Processing (NLP) techniques

Unlock the power of electronic health records (EHR) & design virtual control arms for clinical trials

Company background.

syndena partners with providers, medical societies, payers, and manufacturers to harness F.A.I.R. real-world data for advancing medical research, evaluating patient outcomes and personalize care.

In addition to these efforts, syndena develops state-of-the art artificial intelligence (AI) models and solutions for finding patients for synthetic control arms for clinical trials and predict their clinical outcome.

our partners.

syndena unlocks the power of EHR and generates RWD for health care centers and life sciene companies

scientific references.

Clinical Outcome Assessment in Cancer Rehabilitation and the Central Role of Patient-Reported Outcomes

Jens Lehmann, Maria Rothmund, David Riedl, Gerhard Rumpold, Vincent Grote, Michael J Fischer, Bernhard Holzner. PMID: 35008247
more

Functional health and symptoms in Spain before and during the COVID-19 pandemic

Jens Lehmann, Bernhard Holzner, Johannes M Giesinger, Andrew Bottomley, Shaad Ansari, Ludwig von Butler, Georg Kemmler. PMID: 33933042
more

Implementation of daily patient-reported outcome measurements to support children with cancer

Andreas Meryk, Gabriele Kropshofer, Benjamin Hetzer, David Riedl, Jens Lehmann, Gerhard Rumpold, Alexandra Haid, Bernhard Holzner, Roman Crazzolara. PMID: 34383360
more

Bridging the gap in outpatient care: Can a daily patient-reported outcome measure help?

Andreas Meryk, Gabriele Kropshofer, Benjamin Hetzer, David Riedl, Jens Lehmann, Gerhard Rumpold, Alexandra Haid, Bernhard Holzner, Roman Crazzolara. PMID: 34245127
more

Estimating seroprevalence of SARS-CoV-2 antibodies using three self-reported symptoms: development of a prediction model based on data from Ischgl, Austria

Jens Lehmann, Johannes M Giesinger, Gerhard Rumpold, Wegene Borena, Ludwig Knabl, Barbara Falkensammer, Cornelia Ower, Magdalena Sacher, Dorothee von Laer, Barbara Sperner-Unterweger, Bernhard Holzner. PMID: 33597049
more

The cancer patient’s perspective of COVID-19-induced distress-A cross-sectional study and a longitudinal comparison of HRQOL assessed before and during the pandemic

Karin A Koinig, Christoph Arnold, Jens Lehmann, Johannes Giesinger, Stefan Köck, Wolfgang Willenbacher, Roman Weger, Bernhard Holzner, Ute Ganswindt, Dominik Wolf, Reinhard Stauder. PMID: 33973411
more

The Attitude towards Polypills Questionnaire (APPQ): a phase I-III development and validation study in patients with cerebrovascular disease

Jens Lehmann, David Riedl, Monika Sztankay, Christian Boehme, Julian Fischnaller, Stefan Kiechl, Bernhard Holzner, Michael Knoflach, Gerhard Rumpold. PMID: 34463018
more

Using the Computer-based Health Evaluation System (CHES) to Support Self-management of Symptoms and Functional Health: Evaluation of Hematological Patient Use of a Web-Based Patient Portal

Jens Lehmann, Petra Buhl, Johannes M Giesinger, Lisa M Wintner, Monika Sztankay, Lucia Neppl, Wolfgang Willenbacher, Roman Weger, Walpurga Weyrer, Gerhard Rumpold, Bernhard Holzner. PMID: 34100765
more

The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond

Irene Strassl, Martin Schreder, Normann Steiner, Jakob Rudzki, Hermine Agis, Tina Künz, Nino Müser, Wolfgang Willenbacher, Andreas Petzer, Peter Neumeister, Maria Theresa Krauth. PMID: 34572927
more
more

The cancer patient’s perspective of COVID-19-induced distress-A cross-sectional study and a longitudinal comparison of HRQOL assessed before and during the pandemic

Karin A Koinig, Christoph Arnold, Jens Lehmann, Johannes Giesinger, Stefan Köck, Wolfgang Willenbacher, Roman Weger, Bernhard Holzner, Ute Ganswindt, Dominik Wolf, Reinhard Stauder. PMID: 33973411
more

The Attitude towards Polypills Questionnaire (APPQ): a phase I-III development and validation study in patients with cerebrovascular disease

Jens Lehmann, David Riedl, Monika Sztankay, Christian Boehme, Julian Fischnaller, Stefan Kiechl, Bernhard Holzner, Michael Knoflach, Gerhard Rumpold. PMID: 34463018
more

Using the Computer-based Health Evaluation System (CHES) to Support Self-management of Symptoms and Functional Health: Evaluation of Hematological Patient Use of a Web-Based Patient Portal

Jens Lehmann, Petra Buhl, Johannes M Giesinger, Lisa M Wintner, Monika Sztankay, Lucia Neppl, Wolfgang Willenbacher, Roman Weger, Walpurga Weyrer, Gerhard Rumpold, Bernhard Holzner. PMID: 34100765
more

The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond

Irene Strassl, Martin Schreder, Normann Steiner, Jakob Rudzki, Hermine Agis, Tina Künz, Nino Müser, Wolfgang Willenbacher, Andreas Petzer, Peter Neumeister, Maria Theresa Krauth. PMID: 34572927
more

Complementing clinical cancer registry data with patient reported outcomes: A feasibility study on routine electronic patient-reported outcome assessment for the Austrian Myelome Registry.

Sztankay M, Neppl L, Wintner LM, Loth FL, Willenbacher W, Weger R, Weyrer W, Steurer M, Rumpold G, Holzner B. Eur J Cancer Care (Engl). 2019 Nov;28(6):e13154. doi: 10.1111/ecc.13154. Epub 2019 Aug 29. PMID: 31465136
more
Willenbacher E, Jöhrer K, Willenbacher W, Flögel B, Greil R, Kircher B. Ann Hematol. 2019 Nov;98(11):2569-2578. doi: 10.1007/s00277-019-03797-6. Epub 2019 Oct 18.
more

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.

Ludwig H, Poenisch W, Knop S, Egle A, Schreder M, Lechner D, Hajek R, Gunsilius E, Krenosz KJ, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Melchardt T, Greil R, Zojer N. Br J Cancer. 2019 Oct;121(9):751-757. doi: 10.1038/s41416-019-0581-8. Epub 2019 Sep 27.
more
Terpos E, Jamotte A, Christodoulopoulou A, Campioni M, Bhowmik D, Kennedy L, Willenbacher W. J Med Econ. 2019 Aug;22(8):766-776. doi: 10.1080/13696998.2019.1606002. Epub 2019 Apr 29. PMID: 30969797
more

Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study.

Antlanger M, Dust T, Reiter T, Böhm A, Lamm WW, Gornicec M, Willenbacher E, Nachbaur D, Weger R, Rabitsch W, Rasoul-Rockenschaub S, Worel N, Lechner D, Greinix H, Keil F, Gisslinger H, Agis H, Krauth MT. BMC Cancer. 2018 Oct 20;18(1):1008. doi: 10.1186/s12885-018-4926-0.
more

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.

Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, Durán MS, De Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Pečeliūnas V, Willenbacher W, Silva J, Louw V, Nemet D, Borbényi Z, Abadi U, Pedersen RS, Černelč P, Potamianou A, Couturier C, Feys C, Thoret-Bauchet F, Boccadoro M; EMMOS Investigators. Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e401-e419. doi: 10.1016/j.clml.2018.06.018. Epub 2018 Jun 25.
more

Short overview on the current standard of treatment in newly diagnosed multiple myeloma.

Willenbacher E, Balog A, Willenbacher W. Memo. 2018;11(1):59-64. doi: 10.1007/s12254-018-0383-3. Epub 2018 Feb 21. PMID: 29606980
more

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies.

Willenbacher W, Seeber A, Steiner N, Willenbacher E, Gatalica Z, Swensen J, Kimbrough J, Vranic S. Int J Mol Sci. 2018 Jul 18;19(7):2087. doi: 10.3390/ijms19072087. PMID: 30021955
more

PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.

Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A. Lancet. 2017 Oct 20. pii: S0140-6736(17)32134-7.
more

Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma.

Steiner N, Borjan B, Hajek R, Jöhrer K, Göbel G, Willenbacher W, Kern J, Gunsilius E, Untergasser G. Oncotarget. 2017 Apr 21;8(34):56243-56254
more

Querschnittslähmung durch eine seltene Ursache: Differenzialdiagnose eines sekundären intramedullären Non-Hodgkin-Lymphoms.

Mangesius S, Willenbacher W, Gizewski ER. Rofo. 2017 Oct;189(10):992-994. doi: 10.1055/s-0043-117886. Epub 2017 Sep 14
more

Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project.

Seeber A, Gastl G, Ensinger C, Spizzo G, Willenbacher W, Kocher F, Leitner C, Willenbacher E, Amann A, Steiner N, Eisterer W, Voss A, Russell K, Zwierzina H. Genes Cancer. 2016 Sep;7(9-10):301-308.
more

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.

Kiesewetter B, Willenbacher E, Willenbacher W, Egle A, Neumeister P, Voskova D, Mayerhoefer ME, Simonitsch-Klupp I, Melchardt T, Greil R, Raderer M; AGMT Investigators. Blood. 2017 Jan 19;129(3):383-385. doi: 10.1182/blood-2016-06-720599. Epub 2016 Nov 22
more

Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project.

Seeber A, Gastl G, Ensinger C, Spizzo G, Willenbacher W, Kocher F, Leitner C, Willenbacher E, Amann A, Steiner N, Eisterer W, Voss A, Russell K, Zwierzina H. Genes Cancer. 2016 Sep;7(9-10):301-308.
more

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.

Kiesewetter B, Willenbacher E, Willenbacher W, Egle A, Neumeister P, Voskova D, Mayerhoefer ME, Simonitsch-Klupp I, Melchardt T, Greil R, Raderer M; AGMT Investigators. Blood. 2017 Jan 19;129(3):383-385.
more

CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.

Thangavadivel S, Zelle-Rieser C, Olivier A, Postert B, Untergasser G, Kern J, Brunner A, Gunsilius E, Biedermann R, Hajek R, Pour L, Willenbacher W, Greil R, Jöhrer K. Oncotarget. 2016 Nov 29;7(48):78605-78618.
more

Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?

Mondello P, Steiner N, Willenbacher W, Ferrero S, Ghione P, Marabese A, Pitini V, Cuzzocrea S, Mian M. Oncologist. 2016 Sep;21(9):1107-12.
more

Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study.

Mondello P, Steiner N, Willenbacher W, Wasle I, Zaja F, Zambello R, Visentin A, Mauro E, Ferrero S, Ghione P, Pitini V, Cuzzocrea S, Mian M. Ann Hematol. 2016 Jun;95(7):1107-14.
more
more

Looking back on 5 years of horizon scanning in oncology.

Nachtnebel A, Breuer J, Willenbacher W, Bucsics A, Krippl P, Wild C. Int J Technol Assess Health Care. 2016 Jan;32(1-2):54-60.
more
more
more

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.

Raje N, Vadhan-Raj S, Willenbacher W, Terpos E, Hungria V, Spencer A, Alexeeva Y, Facon T, Stewart AK, Feng A, Braun A, Balakumaran A, Roodman GD. Blood Cancer J. 2016 Jan 8;6:e378
more

90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?

Mondello P, Steiner N, Willenbacher W, Arrigo C, Cuzzocrea S, Pitini V, Mian M. Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):82-8.
more
more

contact us.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

We care about your privacy

For a proper online-experience we recommend you to accept the usage of cookies. Some cookies are necessary for the functionality of this website and can therefore not be deselected. Other cookies help us to personalize the content and to analyze the usage of our website. Third-party cookies will allow advertising personalised especially for you.

For further information please see our „cookie policy“ or our „privacy policy“. You can manage your consent and settings at any time by going to „cookie preferences“ at the bottom left of this page.

Details

Essential cookies

Necessary cookies help make a website usable by enabling basic functions like page navigation. Necessary cookies are not saved by third party services, but only transmitted to the website operator.

Präferenzen

Diese Cookies ermöglichen eine verbesserte Funktion der Website. Sie helfen der Website sich Informationen zu merken: ausgewählte Sprachen, Regionen, Benutzernamen, …. Diese Informationen werden ausschließlich anonym gesammelt.

Analytics & statistics

Cookies for statistics help us to understand how users interact with the provided content on our website and to number out the usage of each page. The relevant information is collected and passed on anonymously to our service provider.

Marketing

Such cookies are collected by service providers for advertising purposes and can be used for creating target group specific advertising.